Diagnostic value of 18 F‐FDG PET / CT versus diffusion‐weighted MRI in detection of residual or recurrent tumors after definitive (chemo) radiotherapy for laryngeal and hypopharyngeal squamous cell carcinoma: A prospective study
Head & Neck · 2024
DOI: 10.1002/hed.27796 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Head & Neck, 2024. Verfasst von Soung Yung Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Spital Muri, Muri, Switzerland. Hauptthemen laut MEDLINE: Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: 2022 Advanced Facility Fund of the University of Seoul.
Abstract (Originalsprache)
Background
Despite advances in treatment, residual or recurrent tumors after definitive (chemo) radiotherapy for laryngeal and hypopharyngeal squamous cell carcinoma (SCC) remain a challenge in clinical management and require accurate and timely detection for optimal salvage therapy. This study aimed to compare the diagnostic value of Fluorine 18 ( 18 F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and diffusion‐weighted magnetic resonance imaging (DW‐MRI) in detecting residual or recurrent tumors after definitive (chemo) radiotherapy for laryngeal and hypopharyngeal SCC.
Methods
A prospective study was conducted on 30 patients who presented with new symptoms after definitive (chemo) radiotherapy for laryngeal ( n = 21) and hypopharyngeal ( n = 9) carcinoma. Both 18 F‐FDG PET/CT and DW‐MRI were performed and histopathologic analysis served as the standard of reference.
Results
Histopathology showed 20 patients as positive and 10 as negative for tumors. 18 F‐FDG PET/CT detected all tumors correctly but was falsely positive in one case. DW‐MRI detected tumors in 18 out of 20 positive patients and correctly excluded tumors in all negative patients. The sensitivity and specificity of 18 F‐FDG PET/CT were 100% and 90%, respectively, while the values for DW‐MRI were 90% and 100%, respectively.
Conclusions
The study concludes that 18 F‐FDG PET/CT is slightly superior to DW‐MRI in detecting residual or recurrent tumors after definitive (chemo) radiotherapy for laryngeal and hypopharyngeal SCC. The combined use of 18 F‐FDG PET/CT and DW‐MRI can potentially improve specificity in therapy response evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Spital Muri, Muri, Switzerland.
- BKH Günzburg, Günzburg, Germany.
- Department of Diagnostic and Interventional Radiology, University Hospital Ulm, Ulm, Germany.
- Department of Life Science, University of Seoul, Seoul, Republic of Korea.
ORCID-Profile: Soung Yung Kim, Jung-Hyun Lee
Förderung
- 2022 Advanced Facility Fund of the University of Seoul
Zitieren
APA
Kim, S. Y., Crook, D., Rosskopf, J., & Lee, J. H. (2024). Diagnostic value of 18 F‐FDG PET / CT versus diffusion‐weighted MRI in detection of residual or recurrent tumors after definitive (chemo) radiotherapy for laryngeal and hypopharyngeal squamous cell carcinoma: A prospective study. Head & Neck. https://doi.org/10.1002/hed.27796
Vancouver
Kim SY, Crook D, Rosskopf J, Lee JH. Diagnostic value of 18 F‐FDG PET / CT versus diffusion‐weighted MRI in detection of residual or recurrent tumors after definitive (chemo) radiotherapy for laryngeal and hypopharyngeal squamous cell carcinoma: A prospective study. Head & Neck. 2024. doi:10.1002/hed.27796
BibTeX
@article{Kim2024,
author = {Kim, Soung Yung and Crook, David and Rosskopf, Johannes and Lee, Jung-Hyun},
title = {Diagnostic value of 18 F‐FDG PET / CT versus diffusion‐weighted MRI in detection of residual or recurrent tumors after definitive (chemo) radiotherapy for laryngeal and hypopharyngeal squamous cell carcinoma: A prospective study},
journal = {Head & Neck},
year = {2024},
doi = {10.1002/hed.27796}
}
EUVIMED